Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

Abstract Background Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and ther...

Full description

Bibliographic Details
Main Authors: Louise Laloi, Natacha Chaumard Billotey, Pierre‐Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, Florent Puisset, Sarah Bertoli, Marion Boissard Simonet, Kamel Laribi, Dyhia Houyou, Alberto Santagostino, Claire Michel, Gabrielle Roth Guepin, Elodie Guerineau, Reza Tabrizi, Mathilde Hunault, Aurélien Giltat, Eléonore Kaphan, Claude Bulabois, Elodie Cartet, Clément Rocher, Florence Lachenal, Stéphane Morisset, Christian Récher, Arnaud Pigneux, Amine Belhabri, Mauricette Michallet, Anne‐Sophie Michallet
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
azacitidine
low‐dose cytarabine
venetoclax
Online Access:https://doi.org/10.1002/cam4.5459

Internet

https://doi.org/10.1002/cam4.5459

Similar Items